- Home
- SWVL vs ADVM Comparison
SWVL vs ADVM Comparison
Compare SWVL & ADVM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SWVL
- ADVM
- Stock Information
- Founded
- SWVL 2017
- ADVM 2006
- Country
- SWVL United Arab Emirates
- ADVM United States
- Employees
- SWVL N/A
- ADVM N/A
- Industry
- SWVL Business Services
- ADVM Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- SWVL Consumer Discretionary
- ADVM Health Care
- Exchange
- SWVL Nasdaq
- ADVM Nasdaq
- Market Cap
- SWVL 44.5M
- ADVM 47.4M
- IPO Year
- SWVL N/A
- ADVM 2014
- Fundamental
- Price
- SWVL $4.15
- ADVM $2.35
- Analyst Decision
- SWVL
- ADVM Strong Buy
- Analyst Count
- SWVL 0
- ADVM 5
- Target Price
- SWVL N/A
- ADVM $23.80
- AVG Volume (30 Days)
- SWVL 6.1K
- ADVM 346.6K
- Earning Date
- SWVL 07-07-2025
- ADVM 08-11-2025
- Dividend Yield
- SWVL N/A
- ADVM N/A
- EPS Growth
- SWVL N/A
- ADVM N/A
- EPS
- SWVL N/A
- ADVM N/A
- Revenue
- SWVL $17,207,362.00
- ADVM $1,000,000.00
- Revenue This Year
- SWVL N/A
- ADVM N/A
- Revenue Next Year
- SWVL N/A
- ADVM $18.82
- P/E Ratio
- SWVL N/A
- ADVM N/A
- Revenue Growth
- SWVL N/A
- ADVM N/A
- 52 Week Low
- SWVL $2.40
- ADVM $1.78
- 52 Week High
- SWVL $8.05
- ADVM $10.14
- Technical
- Relative Strength Index (RSI)
- SWVL 45.93
- ADVM 41.22
- Support Level
- SWVL $3.80
- ADVM $2.14
- Resistance Level
- SWVL $4.48
- ADVM $2.60
- Average True Range (ATR)
- SWVL 0.38
- ADVM 0.22
- MACD
- SWVL -0.05
- ADVM -0.01
- Stochastic Oscillator
- SWVL 42.17
- ADVM 12.39
About SWVL Swvl Holdings Corp
Swvl Holdings Corp is a technology-driven mobility company that aims to provide reliable, safe, cost-effective and environmentally responsible mass transit solutions. It provides mobility solutions for enterprises and government and individual commuters across-multiple markets with clients such as Amazon, Bosch, E&, P&G and Siemens. The Company operates in Egypt, Saudi Arabia and the UAE.
About ADVM Adverum Biotechnologies Inc.
Adverum Biotechnologies Inc is a clinical-stage company that aims to establish gene therapy as a new standard of care for prevalent ocular diseases. It develops gene therapy product candidates intended to provide durable efficacy by inducing sustained expression of a therapeutic protein. Its product candidate, ixoberogene soroparvovec (Ixo-vec), is a single, in-office intravitreal (IVT) injection gene therapy product designed to deliver long-term durable therapeutic levels of aflibercept associated with a robust, sustained treatment response, reducing the treatment burden and fluctuations in macular fluid associated with bolus anti-vascular endothelial growth factor (VEGF) IVT injections.